Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily: Proportion achieving target serum urate
Allopurinol 100‐300 mg daily may leads to lower proportion achieving target serum urate compared with febuxostat 80 mg daily (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily Proportion achieving target serum urate · people with chronic gout Allopurinol 100‐300 mg daily may leads to lower proportion achieving target serum urate compared with febuxostat 80 mg daily (low certainty). Allopurinol for chronic gout (2014) · Cochrane Headline outcomes only | RR 0.56 [0.48, 0.65] | 4 studies · 2618 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.